Organization | LimmaTech Biologics AG

LimmaTech Biologics AG Report issue

For profit Phase 1 Phase 2

Founded: Schlieren Switzerland (2015)

Organization Overview

First Clinical Trial

2015

NCT02388009

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

LimmaTech Biologics AG

Active Ingredients

Drugs in Phase 2 Trials (7)

flexyn2a (2 trials)

inactivated rabies vaccine (Imovax) (1 trial)

kleb4v (1 trial)

menacwy conjugate vaccine (1 trial)

shigella conjugate vaccines (1 trial)

Drugs in Phase 1 Trials (2)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23) (1 trial)

bioconjugate pneumococcal vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Dysentery, Bacillary (Phase 2)

Pneumonia (Phase 1)

Pneumonia, Bacterial (Phase 1)

Pneumonia, Pneumococcal (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 5
# of Trial APIs: 9